Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Net Income towards Common Stockholders (2016 - 2026)

Mimedx's Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$10.9 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders changed N/A to -$10.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.9 million, a 132.97% decrease, with the full-year FY2025 number at $48.6 million, up 15.67% from a year prior.
  • Net Income towards Common Stockholders hit -$10.9 million in Q1 2026 for Mimedx, down from $7.4 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for MDXG hit a ceiling of $44.8 million in Q4 2023 and a floor of -$12.5 million in Q2 2022.
  • Historically, Net Income towards Common Stockholders has averaged $4.6 million across 4 years, with a median of $7.4 million in 2024.
  • The widest YoY moves for Net Income towards Common Stockholders: up 681.83% in 2022, down 281.44% in 2022.
  • Tracing MDXG's Net Income towards Common Stockholders over 4 years: stood at $8.1 million in 2022, then soared by 451.13% to $44.8 million in 2023, then crashed by 83.41% to $7.4 million in 2024, then crashed by 246.01% to -$10.9 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for MDXG at -$10.9 million in Q1 2026, $7.4 million in Q4 2024, and $7.9 million in Q3 2024.